Jason Braun joined Immatics in January 2024 and is responsible for the commercial strategy of Immatics’ TCR-based product candidates.
Having worked in the biotech and pharma industry for 20+ years, Jason joins Immatics with considerable experience in the commercialization of oncology drug candidates. Throughout his career, Jason worked at several mid-to-large-size companies including Amgen, Dendreon, Pharmacyclics (Abbvie) and Kite Pharma (Gilead), among others. As Senior Director of Marketing, Hematology & Oncology at Kite, he led the US marketing team through the launch of YESCARTA™, the first autologous CAR-T therapy for adults with certain types of lymphoma. YESCARTA™ was granted FDA breakthrough designation and accelerated approval.
Jason has an MBA from the Northwestern University Kellogg School of Management, a Masters in Engineering Management, Manufacturing and Operations from Northwestern University and a BsChE in Chemical Engineering from Lehigh University.